PCM
FLXN

Portolan Capital Management’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Portolan Capital Management’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-283,169
Closed -$2.95M – 195
2020
Q3 		$2.95M Buy
+283,169
New +$3.47M 0.33% 96

Other funds holding FLXN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Portolan Capital Management's FLXN Position: Q4 2020 in Review

Portolan Capital Management sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2020, closing a stake of 283,169 shares — an estimated $2.95M sold.

Portolan Capital Management first reported a position in FLXN in Q3 2020 and held it in 1 quarter. The position peaked at $2.95M in Q3 2020. 141 funds tracked by Wall St. Rank hold FLXN as of Q4 2020.

  • Portolan Capital Management reported no remaining Flexion Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Portolan Capital Management sold 283,169 Flexion Therapeutics, Inc. shares in Q4 2020, an estimated $2.95M.
  • Portolan Capital Management first reported a position in Flexion Therapeutics, Inc. in Q3 2020 and held it in 1 quarter.
  • Portolan Capital Management's Flexion Therapeutics, Inc. position peaked at $2.95M in Q3 2020.
  • 141 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2020.

Based on Portolan Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.